Unknown

Dataset Information

0

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.


ABSTRACT: BACKGROUND:Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. METHODS:Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to May 2018 were enrolled in this study. PD-L1 expression in tumor cells (TC) and mismatch repair (MMR) were analyzed by immunohistochemistry. Epstein-Barr virus (EBV) was detected by in situ hybridization. Cancer genome alterations were evaluated by a next-generation sequencing-based panel. High tumor mutation burden (TMB) was defined as more than 10 mutations/megabase. RESULTS:A total of 80 pts were analyzed in this study. Tumor response was evaluated in 72 pts with measurable lesions and 14 pts (19%) had an objective response. Overall response rate (ORR) was significantly higher in pts with ECOGPS 0 in those with PS 1 or 2, MMR-deficient (MMR-D) in those with MMR-proficient (MMR-P), PD-L1+ in TC in those with PD-L1- in TC and PIK3CA mutation in those with PIK3CA wild-type. ORR was 31% in pts with at least one of the following factors; MMR-D, high TMB, EBV+ and PD-L1+ in TC vs. 0% in those without these factors. Progression-free survival was significantly longer in pts with PS 0 than in those with PS 1 or 2, MMR-D than in those with MMR-P, and PD-L1+ in TC than in those with PD-L1- in TC. CONCLUSIONS:Some features were associated with favorable response to nivolumab for AGC. Combining these features might be useful to predict efficacy.

SUBMITTER: Mishima S 

PROVIDER: S-EPMC6357506 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.

Mishima Saori S   Kawazoe Akihito A   Nakamura Yoshiaki Y   Sasaki Akinori A   Kotani Daisuke D   Kuboki Yasutoshi Y   Bando Hideaki H   Kojima Takashi T   Doi Toshihiko T   Ohtsu Atsushi A   Yoshino Takayuki T   Kuwata Takeshi T   Tsuji Akihito A   Shitara Kohei K  

Journal for immunotherapy of cancer 20190131 1


<h4>Background</h4>Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood.<h4>Methods</h4>Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to May 2018 were enrolled in this study. PD-L1 expression in tumor cells (TC) and mismatch repair (MMR) were analyzed by immunohistochemistry. Epstein-Barr virus (EBV) was detected by in situ hybri  ...[more]

Similar Datasets

| S-EPMC9031450 | biostudies-literature
2022-11-27 | GSE189926 | GEO
| S-EPMC7683467 | biostudies-literature
| S-EPMC7500034 | biostudies-literature
| S-EPMC8234739 | biostudies-literature
| S-EPMC5289528 | biostudies-literature
| S-EPMC7071798 | biostudies-literature
| S-EPMC7139949 | biostudies-literature
| S-EPMC8606720 | biostudies-literature
| S-EPMC3612054 | biostudies-literature